- Home
- DXC vs PRCT Comparison
DXC vs PRCT Comparison
Compare DXC & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXC
- PRCT
- Stock Information
- Founded
- DXC 1959
- PRCT 2009
- Country
- DXC United States
- PRCT United States
- Employees
- DXC N/A
- PRCT N/A
- Industry
- DXC EDP Services
- PRCT Medical Specialities
- Sector
- DXC Technology
- PRCT Health Care
- Exchange
- DXC Nasdaq
- PRCT Nasdaq
- Market Cap
- DXC 2.9B
- PRCT 3.2B
- IPO Year
- DXC N/A
- PRCT 2021
- Fundamental
- Price
- DXC $14.22
- PRCT $60.22
- Analyst Decision
- DXC Hold
- PRCT Strong Buy
- Analyst Count
- DXC 6
- PRCT 7
- Target Price
- DXC $17.00
- PRCT $90.00
- AVG Volume (30 Days)
- DXC 1.8M
- PRCT 819.9K
- Earning Date
- DXC 08-07-2025
- PRCT 07-31-2025
- Dividend Yield
- DXC N/A
- PRCT N/A
- EPS Growth
- DXC 356.52
- PRCT N/A
- EPS
- DXC 2.10
- PRCT N/A
- Revenue
- DXC $12,871,000,000.00
- PRCT $249,121,000.00
- Revenue This Year
- DXC N/A
- PRCT $47.40
- Revenue Next Year
- DXC N/A
- PRCT $31.55
- P/E Ratio
- DXC $6.76
- PRCT N/A
- Revenue Growth
- DXC N/A
- PRCT 59.36
- 52 Week Low
- DXC $13.44
- PRCT $47.04
- 52 Week High
- DXC $24.83
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- DXC 36.43
- PRCT 52.43
- Support Level
- DXC $15.46
- PRCT $58.34
- Resistance Level
- DXC $15.99
- PRCT $61.43
- Average True Range (ATR)
- DXC 0.43
- PRCT 2.61
- MACD
- DXC -0.09
- PRCT -0.37
- Stochastic Oscillator
- DXC 4.71
- PRCT 38.21
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.